Frost and Sullivan recognizes Parexel with 2022 Global Customer Value Leadership Award
New Delhi: Based on its recent analysis of the global decentralized clinical trials (DCT) industry, Frost & Sullivan has recognized global clinical research organization (CRO) Parexel with the 2022 Global Customer Value Leadership Award.
The company offers Phase I-IV clinical trial capabilities, integrated consulting expertise, and broad therapeutic expertise to accelerate new therapies for patients. It builds its DCT solutions by collaborating closely with a range of stakeholders and partners to evolve alongside market needs and trends.
"Parexel's patient-focused strategies and approach to ensure every trial is inclusive exemplifies an authentic best practice DCT implementation," said Surbhi Gupta, Frost & Sullivan Best Practices Senior Industry Analyst. "Its overall patients-focused approach offers immense value to existing and new customers, solidifying its reputation in the market."
Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the recipient's unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
Read also: Include more govt sites: CDSCO Panel to Parexel on Clinical Trial of Guselkumab
